Zacks: Brokerages Anticipate ZEALAND PHARMA/S (ZEAL) Will Announce Earnings of -$0.69 Per Share
Brokerages predict that ZEALAND PHARMA/S (NASDAQ:ZEAL) will report earnings per share (EPS) of ($0.69) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ZEALAND PHARMA/S’s earnings. ZEALAND PHARMA/S reported earnings of ($0.58) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 19%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 6th.
On average, analysts expect that ZEALAND PHARMA/S will report full year earnings of ($2.47) per share for the current year. For the next year, analysts forecast that the firm will report earnings of ($1.98) per share, with EPS estimates ranging from ($2.26) to ($1.69). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for ZEALAND PHARMA/S.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last announced its quarterly earnings results on Thursday, November 15th. The company reported $4.69 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $5.20. ZEALAND PHARMA/S had a negative net margin of 483.00% and a positive return on equity of 91.98%.
ZEAL traded up $0.68 during trading on Friday, hitting $12.38. 513 shares of the company traded hands, compared to its average volume of 6,770. The firm has a market cap of $392.48 million, a P/E ratio of -8.41 and a beta of 2.32. ZEALAND PHARMA/S has a one year low of $11.51 and a one year high of $18.91.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Further Reading: Find a Trading Strategy That Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.